Alabama is currently home to 1237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors
NCT04088708
Recruiting
The primary goal of this project is to determine the effects of exercise on the gut microbiome in breast cancer survivors and determine how these changes may relate to psychosocial symptoms such as fatigue.
Gender:
FEMALE
Ages:
Between 18 years and 74 years
Trial Updated:
04/10/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Breast Cancer, Gut Microbiome, Exercise, Fatigue
Register for Updates
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NCT06246110
Recruiting
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Southern Cancer Care, Daphne, Alabama
Conditions: NSCLC
Register for Updates
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
NCT06104280
Recruiting
Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investigate a special set of photosensitive neurons in the retina as an underlying mechanism for circadian rhythm and sleep disturbance from opioid use and medications for OUD that could lead to novel interven... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Opioid Use Disorder, Sleep Disturbance
Register for Updates
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT06099769
Recruiting
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Metastatic Breast Cancer
Register for Updates
Investigating Dynamic Interactions in Distributed Cognitive Control Networks
NCT05927974
Recruiting
The purpose of this study is to investigate the brain activity associated with cognitive tasks (thinking, reasoning, remembering) in order to understand how the brain works during certain tasks and to improve treatment for diseases like dementia and attention deficit disorders. Cognitive (thinking) impairment may include poor memory function, poor attention span, or psychiatric disorders (ex: ADD, depression). The investigators are interested in the brain activity related to these issues, and wa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cognitive Impairment, Dementia, ADD, Depression
Register for Updates
A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
NCT05879718
Recruiting
The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for participants who: * are adults of 18 years of age or older. * are confirmed to have CLE or SLE with involvement of the skin. * have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8. About 48 participants... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2025
Locations: The Kirklin Clinic of UAB Hospital, Birmingham, Alabama
Conditions: Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Huntsville, Alabama
Conditions: Generalized Anxiety Disorder
Register for Updates
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418
Recruiting
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 4
NCT05617014
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
Register for Updates
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
NCT06919328
Recruiting
This study evaluates the subjective effects of injection administration of NR on healthy adult populations.
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
04/07/2025
Locations: Nutraceuticals Research Institute, Huntsville, Alabama
Conditions: Healthy Aging
Register for Updates
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
NCT06829238
Recruiting
This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Register for Updates
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone fo... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/03/2025
Locations: Digestive Health Specialsits, Dothan, Alabama
Conditions: Ulcerative Colitis
Register for Updates